Selecting Cognitive & Behavioral Endpoint Measures for Trials in Rare Epilepsy and MPS Disorders, Upcoming Webinar Hosted by Xtalks

Share Article

Selecting cognitive and behavioral endpoints for rare epilepsy and mucopolysaccharidoses (MPS) trials can be challenging. These diseases are often regressive, making the assessment of cognition and behavior even more complex. Join this free webinar to hear about best practices for selecting endpoint measures for trials in these rare indications. Attendees will learn about various developmental assessments and why they might be used.

Xtalks Life Science Webinars

Several case examples of current trials will be shared, with a focus on differential outcome measures and rationale for their use.

Clinical trials in patients with rare forms of epilepsy and MPS disorders present considerable challenges, as patients with these conditions are heterogeneous and many are quite impaired. Further, comorbid sensory and motor deficits are common as are disruptive behaviors. Additionally, these diseases are often regressive, making the assessment of cognition and behavior even more complex.

On Wednesday, November 20, 2019 at 11am EST (4pm GMT/UK), join Dr. Pamela Ventola, Senior Science Director of Pediatrics and Rare Disease at Cogstate in a live webinar where she will describe the critical factors to consider when selecting cognitive and behavioral endpoints for these trials, including perspectives from regulatory agencies.

Dr. Ventola will describe common measures such as developmental assessments (e.g., Bayley-4 and Mullen), the Wechsler Scales, Kaufman Assessment Battery for Children-Second Edition and the Vineland Adaptive Behavior Scales-Third Edition. She will differentiate between the measures so attendees will be better positioned to select outcome assessments based on the specific indication and needs of the trial.

Several case examples of current trials will be shared, with a focus on differential outcome measures and rationale for their use.

For more information or to register for this event, visit Selecting Cognitive & Behavioral Endpoint Measures for Trials in Rare Epilepsy and MPS Disorders.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
(416) 977-6555 227
Email >
Visit website